BioLineRx gains orphan status for novel stem cell mobilization treatment – The Pharma Letter
|
BioLineRx gains orphan status for novel stem cell mobilization treatment
The Pharma Letter Israeli drug developer BioLineRx (TASE: BLRX) has received notice from the US Food and Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the orphan status previously granted … |
